2013-11-14T15:26:51-06:00 2012-12-31 861065772 DELOITTE TAX LLP 655 WEST BROADWAY SUITE 700 SAN DIEGO CA 921018590 990 2012-01-01 330328688 LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY LAJO 8587526500 9420 ATHENA CIRCLE LA JOLLA CA 920371387 301510 8587526500 2013-11-14 1 DIANA J MCCUTCHEN P00545657 6192326500 2012 2016-02-24 21:20:13Z CHARLES CARPOWICH 9420 ATHENA CIRCLE LA JOLLA CA 920371387 49232647 0 X WWW.LJI.ORG X 1988 CA BIOMEDICAL RESEARCH MAKING BREAKTHROUGH DISCOVERIES LEADING TO NEW TREATMENTS AND CURES. 13 11 382 48 195196 51591 43377978 43599639 3608126 3110250 103116 137229 1345748 2385529 48434968 49232647 0 4900 0 0 24872839 25931888 0 245000 393992 21441400 21895381 46314239 48077169 2120729 1155478 27262976 29571824 9065851 10219221 18197125 19352603 X AT LA JOLLA INSTITUTE, OUR SCIENTISTS FOCUS ON HARNESSING THE IMMENSE POWER OF THE IMMUNE SYSTEM TO PROMOTE HEALTH AND PREVENT DISEASE. OUR RESEARCH COVERS A BROAD SPECTRUM OF DISORDERS RANGING FROM DIABETES TO HEART DISEASE TO INFECTIOUS DISEASES TO CANCER. 0 0 42266140 4900 3110250 LA JOLLA INSTITUTE IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE RANKED AMONG THE TOP FIVE ORGANIZATIONS IN THE WORLD FOR RESEARCH IMPACT IN IMMUNOLOGY. SPECIFICALLY, OUR SCIENTISTS CARRY OUT RESEARCH TO UNDERSTAND HOW THE IMMUNE SYSTEM WORKS, AND TO APPLY THAT KNOWLEDGE TO PREVENT OR CURE DISEASE. IMMUNE SYSTEM DISORDERS AFFECT MILLIONS AND INCLUDE MANY OF SOCIETY'S MOST DEBILITATING ILLNESSES. OUR RESEARCH FOCUSES ON FIVE MAJOR AREAS: 1. AUTOIMMUNE DISEASES SUCH AS TYPE 1 DIABETES AND RHEUMATOID ARTHRITIS 2. CANCER AND STIMULATING ANTI-TUMOR RESPONSES 3. INFECTIOUS DISEASES AND VACCINE DEVELOPMENT TO COMBAT TUBERCULOSIS, FLU, DENGUE VIRUS, AND OTHER DANGEROUS PATHOGENS 4. ALLERGY AND ASTHMA AND CONTROLLING HARMFUL IMMUNE REACTIONS 5. VASCULAR IMMUNOLOGY INCLUDING HEART DISEASE AND TYPE 2 DIABETES.MILLIONS OF PEOPLE AROUND THE WORLD DIE EACH YEAR FROM DISEASES THAT COULD BE CURED OR PREVENTED IF THE IMMUNE SYSTEM WERE FUNCTIONING PROPERLY. LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY IS RECOGNIZED AS A WORLD LEADER IN RESEARCH FOCUSED ON HARNESSING THE IMMUNE SYSTEM'S MECHANISMS TO PROMOTE HEALTH AND PREVENT DISEASE. LA JOLLA INSTITUTE SCIENTISTS BRING TO BEAR A COMPREHENSIVE RESEARCH EFFORT TO UNDERSTAND THE DIVERSE ASPECTS OF IMMUNE-MEDIATED DISEASES, WHICH INCLUDE MANY OF SOCIETY'S MOST DEBILITATING ILLNESSES. THESE RANGE FROM CHRONIC, SEVERE AUTOIMMUNE DISORDERS SUCH AS RHEUMATOID ARTHRITIS, TYPE 1 DIABETES, MULTIPLE SCLEROSIS, AND CROHN'S DISEASE TO IMMUNE SYSTEM MALFUNCTIONS UNDERLYING HEART DISEASE AND CANCER, THE NATION'S NO. 1 AND NO. 2 KILLERS RESPECTIVELY. ITS RESEARCHERS ALSO EXPLORE HOW THE IMMUNE SYSTEM RESPONDS TO INFECTIOUS DISEASES AND IS USING THIS KNOWLEDGE TO ADVANCE THE DEVELOPMENT OF VACCINES AGAINST DEADLY PATHOGENS SUCH AS MALARIA, TUBERCULOSIS, AND DENGUE FEVER, WHERE NO EFFECTIVE VACCINES CURRENTLY EXIST. A NONPROFIT, THE INSTITUTE WAS FOUNDED IN 1988 AND IS HOME TO 22 INDEPENDENT LABORATORIES, EACH OPERATED BY A LEADING SCIENTIST WHO OVERSEES EFFORTS TO UNLOCK THE MYSTERIES OF IMMUNE SYSTEM FUNCTIONING. SUPPORTING THESE EFFORTS ARE THE INSTITUTE'S MORE THAN 350 EMPLOYEES - ABOUT HALF OF WHOM HOLD DOCTORAL DEGREES (PH.D. OR M.D.) FROM NUMEROUS COUNTRIES AROUND THE WORLD. ALTHOUGH RELATIVELY YOUNG, THE INSTITUTE HAS ACCOMPLISHED MUCH IN ITS SHORT HISTORY, AND WAS RECENTLY RANKED AMONG THE TOP FIVE ORGANIZATIONS FOR RESEARCH IMPACT IN IMMUNOLOGY WORLDWIDE (AS MEASURED BY CITATIONS PER SCIENTIFIC PUBLICATION) BY THE RATING AGENCY THOMSON-REUTERS. IN ADDITION, THREE OF ITS SCIENTISTS ARE AMONG THE MOST HIGHLY CITED IMMUNOLOGISTS IN THE WORLD -- A DISTINCTION HELD BY LESS THAN ONE HALF OF ONE PERCENT OF ALL PUBLISHING SCIENTIFIC AUTHORS. SEVERAL OF ITS FACULTY MEMBERS ALSO SERVE ON NATIONAL INSTITUTES OF HEALTH (NIH) GRANT REVIEW PANELS, WHICH ARE APPOINTMENTS THAT SIGNAL A HIGH DEGREE OF RESPECT FROM PEERS. ITS SCIENTISTS ALSO REGULARLY PUBLISH RESEARCH PAPERS DESCRIBING THEIR LATEST FINDINGS, MANY OF THESE APPEARING IN THE WORLD'S MOST PRESTIGIOUS SCIENTIFIC JOURNALS.THE INSTITUTE RECEIVES THE MAJORITY OF ITS FUNDING THROUGH COMPETITIVE RESEARCH GRANTS FROM THE NIH AND IS GROWING ITS PHILANTHROPIC OPPORTUNITIES TO FULFILL PRIORITY NEEDS. THIS INCLUDES FUNDING FOR NEW AREAS OF RESEARCH, CUTTING-EDGE TECHNOLOGIES AND CONTINUING RECRUITMENT OF THE VERY BEST SCIENTISTS.IT IS GUIDED BY A BOARD OF DIRECTORS COMPOSED OF RESPECTED BUSINESS EXECUTIVES, SCIENTISTS AND OTHER COMMUNITY LEADERS WHO DONATE THEIR TIME TO OVERSEE THE INSTITUTE'S ACTIVITIES. A SCIENTIFIC ADVISORY BOARD OF DISTINGUISHED OUTSIDE SPECIALISTS CONDUCTS ANNUAL EVALUATIONS OF SCIENTIFIC PROGRESS AND REVIEWS FUTURE RESEARCH OBJECTIVES.LA JOLLA INSTITUTE RESEARCHERS CONTINUED TO MAKE IMPRESSIVE RESEARCH ADVANCEMENTS IN 2012, WITH 155 RESEARCH PAPERS PUBLISHED IN SCIENTIFIC JOURNALS, AN INCREASE OF MORE THAN 10 PERCENT OVER THE PREVIOUS YEAR. ALONG WITH INCREASING IN NUMBER, MANY OF THE INSTITUTE'S 2012 PAPERS (MORE THAN 20 PERCENT) WERE PUBLISHED IN HIGH-IMPACT, HIGH-PRESTIGE JOURNALS, A REFLECTION OF THE EXEMPLARY QUALITY OF THE INSTITUTE'S RESEARCH. THE INSTITUTE'S MAJOR PUBLISHED FINDINGS IN 2012 ILLUSTRATE THE RANGE AND POWER OF IMMUNOLOGY RESEARCH AND ITS IMPACT ON A BROAD GROUP OF HUMAN HEALTH ISSUES. THIS INCLUDED DR. KLAUS LEY'S DISCOVERY OF KEY INFLAMMATORY MECHANISMS THAT WORSEN ARTERIAL PLAQUE BUILDUP - A GROUNDBREAKING FINDING THAT LED TO HIS CURRENT EFFORTS TO DEVELOP A FIRST-EVER VACCINE FOR HEART DISEASE. SUCH A VACCINE WOULD WORK BY TEACHING THE BODY TO TOLERATE, RATHER THAN ATTACK, CERTAIN IMMUNE CELLS IN THE ARTERY WALL, THEREBY STOPPING THE INFLAMMATION THAT SIGNIFICANTLY FUELS PLAQUE BUILDUP. IF SUCCESSFUL, THE VACCINE WOULD PROVIDE DOCTORS A MAJOR NEW TOOL TO AID IN THE PREVENTION OF HEART DISEASE. AMONG THE INSTITUTE'S OTHER MAJOR FINDINGS IN 2012 WERE: DR. MITCHELL KRONENBERG'S DISCOVERY, PUBLISHED IN NATURE, OF A MOLECULE'S PREVIOUSLY UNKNOWN ROLE IN FIGHTING E. COLI AND OTHER BACTERIAL INFECTIONS, AN IMPORTANT REVELATION THAT COULD LEAD TO NEW TREATMENTS TO PROTECT PEOPLE FROM THESE DANGEROUS MICROORGANISMS; DR. BJOERN PETER'S IDENTIFICATION OF THE CELLULAR MECHANISM UNDERLYING POTENTIALLY FATAL DRUG REACTIONS IN MANY PEOPLE, A DISCOVERY THAT MAY ONE DAY ENABLE PRE-SCREENING TO PROTECT PEOPLE AT RISK OF THESE ALLERGIC DRUG REACTIONS, AND DR. MATTHIAS VON HERRATH'S FINDING OF THE SPECIFIC IMMUNE CELLS WHICH TRIGGER THE PANCREATIC BETA CELL DESTRUCTION UNDERLYING TYPE 1 DIABETES. THIS RESEARCH VERIFIES IN HUMANS INFORMATION PREVIOUSLY ONLY SHOWN IN MOUSE STUDIES AND PROVIDES A KEY CELLULAR TARGET FOR FIGHTING THIS DISEASE.IN ADDITION, FIVE INSTITUTE DISCOVERIES, UNDERLYING A NUMBER OF POTENTIAL THERAPIES, ADVANCED IN THE PHARMACEUTICAL PIPELINE IN 2012, THREE OF THEM IN CLINICAL TRIALS. THESE INCLUDE A TRIAL ON A NEW THERAPY FOR CROHN'S DISEASE AND ULCERATIVE COLITIS AND ANOTHER TRIAL, NOW ENTERING PHASE II, ON SICKLE CELL ANEMIA, A DEVASTATING ILLNESS THAT AFFECTS 100,000 AMERICANS AND SEVERAL MILLION PEOPLE WORLDWIDE. OTHER MAJOR HIGHLIGHTS IN 2012 INCLUDE: - RECOGNIZED AS A "BEST PLACE TO WORK" IN THE U.S. RESEARCH COMMUNITY -- THE INSTITUTE EARNED THE NATION'S NUMBER 7 SPOT FOR "BEST PLACES TO WORK FOR POSTDOCS." THE RANKING WAS BASED ON A U.S. SURVEY OF 2,081 POSTGRADUATE RESEARCHERS, KNOWN IN THE SCIENTIFIC COMMUNITY AS "POSTDOCS," CONDUCTED BY THE SCIENTIST MAGAZINE. POSTDOCS HAVE COMPLETED THEIR DOCTORAL DEGREES (PH.D., M.D., OR EQUIVALENT) AND TYPICALLY SPEND SEVERAL YEARS AT A RESEARCH INSTITUTION, GAINING TRAINING AND EXPERIENCE UNDER SENIOR SCIENTISTS. THE INSTITUTE ALSO RECEIVED HIGH MARKS AMONG ITS SENIOR SCIENTISTS, SCORING NUMBER 6 IN THE SCIENTIST'S "BEST PLACES TO WORK IN ACADEMIA" WORLDWIDE SURVEY IN 2012.- MAJOR AWARDS RECEIVED BY SEVERAL RESEARCHERS: DR. SHANE CROTTY WAS SELECTED FOR THE PRESTIGIOUS BIOSCIENCES INVESTIGATOR AWARD IN RECOGNITION OF HIS GROUNDBREAKING WORK IN VACCINE RESEARCH. THE AWARD IS PRESENTED ANNUALLY BY THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS (AAI) AND RECOGNIZES EARLY-CAREER INVESTIGATORS FOR OUTSTANDING RESEARCH CONTRIBUTIONS TO THE FIELD OF IMMUNOLOGY; DR. RENATA M. PEREIRA, A RESEARCHER EXPLORING GENETIC CHANGES IN LEUKEMIA, WAS CHOSEN AS A PEW LATIN AMERICAN FELLOW IN THE BIOMEDICAL SCIENCES. DR. RENATA WAS ONE OF 10 EXCEPTIONAL YOUNG RESEARCHERS SELECTED NATIONWIDE FOR THE PRESTIGIOUS AWARD, WHICH PEW GIVES ANNUALLY TO ENABLE POSTDOCTORAL-LEVEL, LATIN AMERICAN SCIENTISTS TO WORK IN TOP LABORATORIES IN THE UNITED STATES. DR. PEREIRA CAME TO THE U.S. IN 2011 TO WORK IN THE LAB OF DR. ANJANA RAO, A PROMINENT GENETICS AND CELL BIOLOGY RESEARCHER AND A MEMBER OF THE NATIONAL ACADEMY OF SCIENCES; DR. KLAUS LEY WAS HONORED WITH A SPECIAL RECOGNITION AWARD IN VASCULAR BIOLOGY FROM THE AMERICAN HEART ASSOCIATION (AHA). THE AWARD WAS PRESENTED BY THE AHA'S COUNCIL ON ATHEROSCLEROSIS,THROMBOSIS AND VASCULAR BIOLOGY AND RECOGNIZES DR. LEY'S MANY CONTRIBUTIONS TO THE FIELD, WHICH FOCUSES ON HEART ATTACK, STROKE, AND PERIPHERAL ARTERIAL DISEASE. IN ADDITION TO THEIR RESEARCH ACTIVITIES IN 2012, INSTITUTE SCIENTISTS ALSO LECTURED AT MEDICAL RESEARCH SEMINARS THROUGHOUT THE WORLD AND ORGANIZED NUMEROUS SCIENTIFIC CONFERENCES. WHILE IT IS DIFFICULT TO DETERMINE THE NUMBER OF PERSONS BENEFITED BECAUSE OF THE BROAD APPLICABILITY OF LA JOLLA INSTITUTE'S FINDINGS AND ACCOMPLISHMENTS, THE INSTITUTE ESTIMATES THAT THOUSANDS OF RESEARCH AND CLINICAL SCIENTISTS ATTENDED THE ABOVE MENTIONED CONFERENCES, READ THE INSTITUTE'S PUBLICATIONS, AND/OR DIRECTLY COLLABORATED WITH OUR SCIENTISTS, AND AS A RESULT, NOW INCORPORATE PORTIONS OF OUR RESEARCH INTO THEIR WORK TO BETTER UNDERSTAND THE COMPLEXITY OF HUMAN BIOLOGY TO MORE EFFECTIVELY FIGHT DISEASE. 42266140 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 1 109 0 1 382 1 1 1 0 0 0 0 0 0 0 0 0 0 X 13 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA CT NY OH VA IL MD NC FL MI WI AZ NJ PA WA GA RI UT MO TX MT X CHARLES CARPOWICH 8587526500 9420 ATHENA CIRCLE LA JOLLA CA 920371387 MITCHELL KRONENBERG PHD 40.00 X X 413510 0 49518 CHARLES J CASHION 2.00 X 0 0 0 DAVID DOMINGUEZ 2.00 X 0 0 0 ROBERT C DYNES PHD 2.00 X 0 0 0 LEROY HOOD MD PHD 2.00 X 0 0 0 RICHARD K KORNFELD 2.00 X 0 0 0 JOHN E MAJOR 2.00 X 0 0 0 TOSHIFUMI MIKAYAMA PHD 2.00 X 0 0 0 GAIL K NAUGHTON PHD 2.00 X 0 0 0 DAVID A PERKINS 2.00 X 0 0 0 RHONDA F RHYNE 2.00 X 0 0 0 SAMUEL STROBER MD 2.00 X 1500 0 0 DAVID R WEBB PHD 2.00 X 0 0 0 MARK FISCHER 2.00 X 0 0 0 MICHAEL MARTIN 2.00 X 0 0 0 WILLIAM ROHN 2.00 X 0 0 0 CHARLES CARPOWICH 40.00 X 310727 0 57528 AMNON ALTMAN 40.00 X 302363 0 52293 STEPHEN WILSON 40.00 X 223874 0 55528 HILDE CHEROUTRE 40.00 X 248224 0 45471 KLAUS LEY 40.00 X 287914 0 52274 JOEL LINDEN 40.00 X 279108 0 46076 ANJANA RAO 40.00 X 303593 0 46076 ALESSANDRO SETTE 40.00 X 305974 0 57528 MARYANN STEWART 0.00 X 130744 0 0 2807531 0 462292 41 1 1 0 SOL PACIFIC LLC 6336 GREENWICH DR SUITE B SAN DIEGO CA 92122 JANITORIAL SERVICES 153745 PILLSBURY WINTHROP SHAW PITTMAN POBOX 7422262 LOS ANGELES CA 900742262 LEGAL SERVICES-PATENT 127584 2 109744 33828650 9661245 43599639 CONSORTIUM REVENUE 900099 3110250 3110250 3110250 137229 137229 1986252 1986252 OTHER INCOME 900099 204081 204081 TECHNICAL SERVICES 541900 159810 159810 BUILDING MANAGEMENT 561700 35386 35386 399277 49232647 3110250 195196 2327562 4900 4900 1466841 1290820 171259 4762 293696 293696 18086198 15656481 2403119 26598 1792698 1545124 243942 3632 2995830 2491874 501297 2659 1296625 1141031 152934 2660 233461 192485 40976 174443 174443 3720 3720 245000 245000 134340 78075 56265 630710 47401 510379 72930 228948 194247 32662 2039 687069 418592 265878 2599 4963458 4533575 415202 14681 214959 207792 7167 208266 195718 12030 518 1965589 1844940 120649 159594 144372 15222 LAB SUPPLIES 8026429 8017565 8864 0 CONSORTIUM 2847738 2847738 0 MINOR EQUIPMENT 459420 420875 38545 0 RESEARCH CONSULTANT FEE 150274 150274 806963 548565 242484 15914 48077169 42266140 5417037 393992 2568 2568 10789915 10870871 6254903 8798256 293750 116666 120647 369408 401515 714806 19991734 11292485 9399678 8699249 27262976 29571824 8329223 9172372 736628 1046849 0 9065851 10219221 X 17945093 19125549 252032 227054 18197125 19352603 27262976 29571824 1155478 0 X 0 1 X 1 1 1 X UCSD MEDICAL CENTER SAN DIEGO CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 1 3720 3720 0 EXPLANATION OF LOBBYING ACTIVITIES: PART II-B, LINE 1: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY IS A MEMBER OF THE ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES AND RESEARCH! AMERICA. THESE ORGANIZATIONS DESIGNATE A PORTION OF THE DUES THEY RECEIVE FOR LOBBYING ACTIVITIES. 5891316 1678078 4213238 13211350 8912890 4298460 889068 701517 187551 8699249 49129706 0 49129706 102941 102941 49232647 47974228 0 47974228 102941 102941 48077169 PART XI, LINE 4B - OTHER ADJUSTMENTS: EXPENSES NETTED AGAINST REVENUE ON AUDITED FINANCIAL STATEMENTS 102,941. PART XII, LINE 4B - OTHER ADJUSTMENTS: EXPENSES NETTED AGAINST REVENUE ON AUDITED FINANCIAL STATEMENTS 102,941. 1 EUROPE (INCLUDING ICELAND & GREENLAND) SUBCONTRACTS 14337 MIDDLE EAST AND NORTH AFRICA SUBCONTRACTS 24268 SOUTH AMERICA SUBCONTRACTS 86127 0 0 0 0 0 0 124732 0 124732 0 0 0 0 0 0 X X 1 GREENWOOD COMPANY 201 CALIFORNIA STREET STE 630 SAN FRANCISCO CA 94111 DESIGNS DEVELOPMENT PROGRAMS 0 0 245000 -245000 245000 -245000 CA CT NY OH VA IL MD NC FL MI WI AZ NJ PA WA GA RI UT MO TX MT X X X X X 1 0 0 0 0 0 0 0 0 MITCHELL KRONENBERG PHD 390308 0 0 0 23202 0 37500 0 12018 0 463028 0 0 0 CHARLES CARPOWICH 280237 0 0 0 30490 0 37500 0 20028 0 368255 0 0 0 AMNON ALTMAN 258981 0 0 0 43382 0 37500 0 14793 0 354656 0 0 0 STEPHEN WILSON 223366 0 0 0 508 0 35500 0 20028 0 279402 0 0 0 HILDE CHEROUTRE 226460 0 0 0 21764 0 36877 0 8594 0 293695 0 0 0 KLAUS LEY 260386 0 0 0 27528 0 37500 0 14774 0 340188 0 0 0 JOEL LINDEN 257132 0 0 0 21976 0 37500 0 8576 0 325184 0 0 0 ANJANA RAO 281237 0 0 0 22356 0 37500 0 8576 0 349669 0 0 0 ALESSANDRO SETTE 269061 0 0 0 36913 0 37500 0 20028 0 363502 0 0 0 MARYANN STEWART 0 0 0 0 130744 0 0 0 0 0 130744 0 0 0 PART I, LINE 4A MARYANN STEWART RECEIVED A SEVERANCE PAYMENT OF $130,744 IN CALENDAR YEAR 2012. SEE PART V X 250000 116666 0 1 1 116666 SEE PART V 0 SCHEDULE L, PART II, LOANS TO AND FROM INTERESTED PERSONS: (A) NAME OF PERSON: KLAUS LEY(B) RELATIONSHIP WITH ORGANIZATION: HIGHEST COMPENSATED EMPLOYEE(C) PURPOSE OF LOAN: HOUSING LOAN(E) ORIGINAL PRINCIPAL AMOUNT: $250,000(F) BALANCE DUE: $116,666 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: HILDE CHEROUTRE(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: SPOUSE OF PRESIDENT AND CSO (C) AMOUNT OF TRANSACTION $248,224(D) DESCRIPTION OF TRANSACTION: FULL TIME EMPLOYEE(E) SHARING OF ORGANIZATION REVENUES? = NO(A) NAME OF PERSON: KYOWA HAKKO KIRIN CALIFORNIA INC. ("KKC")(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION:AN OFFICER OF KKC IS A DIRECTOR OF THE INSTITUTE (C) AMOUNT OF TRANSACTION $6,905,103(D) DESCRIPTION OF TRANSACTION:RESEARCH FUNDING, FACILITY RENT, COST REIMBURSEMENTS (E) SHARING OF ORGANIZATION REVENUES? = NO FORM 990, PART VI, SECTION B, LINE 11 IN ACCORDANCE WITH WRITTEN INSTITUTE POLICY, A DRAFT OF FORM 990 IS PROVIDED TO ALL BOARD MEMBERS FOR THEIR REVIEW AND COMMENT PRIOR TO FILING THE RETURN. COMMENTS AND SUGGESTED CHANGES TO THE DRAFT ARE INCORPORATED INTO THE FINAL VERSION OF FORM 990. FORM 990, PART VI, SECTION B, LINE 12C THE INSTITUTE ADMINISTERS THREE SEPARATE CONFLICT OF INTEREST POLICIES APPLYING TO 1) THE BOARD OF DIRECTORS, 2) FACULTY AND SENIOR ADMINISTRATION, AND 3) AN INVESTIGATOR FINANCIAL CONFLICT OF INTEREST POLICY REQUIRED UNDER NATIONAL INSTITUTES OF HEALTH REGULATIONS. THE INSTITUTE REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THESE POLICIES IN ACCORDANCE WITH WRITTEN PROCEDURES, WHICH INCLUDE THE COMPLETION OF DISCLOSURE FORMS BY COVERED INDIVIDUALS, EVALUATION OF COMPLETED FORMS BY A DESIGNATED CONFLICT REVIEW OFFICER, AND AS NECESSARY, FURTHER EVALUATION AND DETERMINATION BY A DESIGNATED CONFLICT REVIEW COMMITTEE. IF A CONFLICT IS DETERMINED, A MANAGEMENT PLAN IS DESIGNED AND MONITORED FOR THE SPECIFIC SITUATION. SUCH PLAN MAY REQUIRE THE COVERED INDIVIDUAL TO ELIMINATE THE CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION DECISIONS FOR THE INSTITUTE'S CEO AND OTHER KEY EMPLOYEES ARE MADE ANNUALLY. ADJUSTMENTS, IF ANY, TYPICALLY TAKE EFFECT ON A JANUARY 1ST CYCLE. FOR THESE PURPOSES, THE INSTITUTE'S HUMAN RESOURCES DEPARTMENT OBTAINS RELEVANT MARKET COMPARABILITY DATA FOR EACH POSITION ON AN ANNUAL BASIS. THE INSTITUTE ALSO PERIODICALLY ENGAGES AN INDEPENDENT COMPENSATION CONSULTING FIRM TO PERFORM COMPENSATION STUDIES FOR KEY INDIVIDUALS AND TO EVALUATE THE INSTITUTE'S EXECUTIVE COMPENSATION AND BENEFITS PROGRAMS FOR REASONABLENESS. IN ACCORDANCE WITH ITS CHARTER, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS REVIEWS AND DISCUSSES THIS INFORMATION, AND THE PERFORMANCE OF THE INSTITUTE'S CEO AND KEY EMPLOYEES, AND FORMULATES RECOMMENDED COMPENSATION ACTIONS TO THE FULL BOARD OF DIRECTORS. THE BOARD OF DIRECTORS REVIEWS THESE RECOMMENDATIONS AND RELATED INFORMATION IN DECIDING COMPENSATION LEVELS FOR EACH POSITION. FORM 990, PART VI, SECTION C, LINE 19 THE INSTITUTE MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. SUMMARIZED FINANCIAL DATA IS ALSO MADE AVAILABLE AS PART OF THE INSTITUTE'S ANNUAL REPORT, WHICH IS WIDELY DISTRIBUTED, AND CAN BE DOWNLOADED FROM THE INSTITUTE'S WEB SITE.